Unjha Formulations Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Show Marked Improvement

Unjha Formulations currently trades at a price of ₹28.10, up 2.18% from the previous close of ₹27.50, with a 52-week high of ₹29.50 and a low of ₹17.52. The company’s price-to-earnings (P/E) ratio stands at 17.73, a figure that places it comfortably below many of its peers in the sector, reflecting a more reasonable valuation relative to earnings. This P/E ratio is a key driver behind the upgrade in the valuation grade from very attractive to attractive, indicating that the stock is now priced more favourably compared to its historical levels and peer averages.

In addition, the price-to-book value (P/BV) ratio is 3.28, which, while higher than some peers, remains within an acceptable range for a company demonstrating strong returns on capital. The enterprise value to EBITDA (EV/EBITDA) ratio of 10.74 further supports the view that Unjha Formulations is trading at a discount relative to its earnings before interest, tax, depreciation, and amortisation, especially when compared to other companies in the Pharmaceuticals & Biotechnology sector.

Comparative Peer Analysis Highlights Relative Attractiveness

When benchmarked against key competitors, Unjha Formulations’ valuation stands out as attractive. For instance, Hester Biosciences trades at a P/E of 40.47 and an EV/EBITDA of 26.96, categorised as very expensive. Similarly, NGL Fine Chem and Jagsonpal Pharma carry P/E ratios above 32 and EV/EBITDA multiples exceeding 22, underscoring their premium valuations. In contrast, Unjha’s P/E of 17.73 and EV/EBITDA of 10.74 suggest a more reasonable entry point for investors.

Venus Remedies and Fermenta Biotec, with P/E ratios of 18.03 and 20.38 respectively, are rated fair, while Fredun Pharma and Syncom Formulations, with P/E ratios of 41.89 and 16.03, are also considered attractive or better. This peer context reinforces Unjha Formulations’ position as a competitively valued micro-cap within the sector.

Strong Financial Returns Bolster Valuation Appeal

Unjha Formulations boasts a robust return on capital employed (ROCE) of 40.00% and a return on equity (ROE) of 18.49%, both indicative of efficient capital utilisation and profitability. These metrics are critical in justifying the current valuation multiples and suggest that the company is generating substantial returns relative to its asset base and shareholder equity.

The company’s enterprise value to capital employed (EV/CE) ratio of 4.98 and EV to sales ratio of 0.70 further highlight its operational efficiency and undervaluation relative to sales and capital investment. The PEG ratio of 0.23, which adjusts the P/E ratio for earnings growth, signals that the stock is undervalued relative to its growth prospects, a compelling factor for growth-oriented investors.

Stock Performance Outpaces Market Benchmarks

Unjha Formulations has delivered impressive returns relative to the broader market. Over the past week, the stock surged 17.62%, vastly outperforming the Sensex’s 2.01% gain. The one-month return is even more striking at 41.56%, dwarfing the Sensex’s 1.90% rise. Year-to-date, the stock has appreciated 12.40%, while the Sensex has declined by 8.56%, signalling strong relative momentum.

Longer-term performance is equally compelling. Over one year, Unjha Formulations returned 9.85% compared to the Sensex’s negative 4.36%. Over three and five years, the stock has delivered extraordinary gains of 141.82% and 167.62% respectively, far exceeding the Sensex’s 17.79% and 48.19% returns. Even on a decade horizon, the stock’s 301.43% appreciation outstrips the Sensex’s 177.80%, underscoring its sustained growth trajectory.

Mojo Score and Grade Reflect Cautious Optimism

The company’s current Mojo Score stands at 34.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell on 08 July 2026. This upgrade reflects improved fundamentals and valuation metrics, though the micro-cap status and sector volatility warrant a cautious stance. The market cap grade remains micro-cap, indicating higher risk and lower liquidity compared to larger peers.

Investors should weigh the attractive valuation and strong returns against the inherent risks of smaller pharmaceutical companies, including regulatory challenges and competitive pressures. The absence of a dividend yield also suggests that returns are primarily driven by capital appreciation rather than income generation.

Outlook and Investor Considerations

Unjha Formulations’ improved valuation profile, combined with strong operational returns and robust stock performance, presents an intriguing opportunity for investors focused on the Pharmaceuticals & Biotechnology sector. The attractive P/E and EV/EBITDA multiples relative to peers suggest the stock is undervalued, while the PEG ratio below 0.25 indicates potential for earnings growth to drive further price appreciation.

However, the micro-cap classification and a Mojo Grade of Sell highlight the need for prudence. Investors should consider the company’s liquidity constraints and sector-specific risks, including regulatory changes and competitive dynamics. Monitoring quarterly earnings and sector developments will be crucial to reassessing the stock’s valuation and growth prospects.

In summary, Unjha Formulations Ltd has transitioned to a more favourable valuation stance, supported by strong financial metrics and market outperformance. While risks remain, the stock’s price attractiveness relative to peers and historical levels makes it a noteworthy candidate for value-oriented portfolios within the pharmaceuticals space.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →